Predicting Future Standard of Care with SGLT2 Inhibitors to Design Relevant Clinical Trials
Time: 8:30 am
day: Day Two
- What will the standard of care look like in drug development for CKD?
- Designing trials that will allow for the inclusion of novel therapies alongside SGLT2 inhibitors
- Considering the future standard of care: combining SGLT2 inhibitors with multiple therapies